I always expected the 6 months post the last patient. It is my belief that once submitted, the NSS will be rapidly approved. It is then up to the company to manage a smooth and efficient scale-up of production. And since that involves current management, I'll honestly say it is a cause for some concern, since they have shown themselves to be a bit amateurish. I do believe this becomes the standard of care for acute AIS-A thoracic. Hopefully migration to cervical looks promising in clinical, and can be abbreviated and added on in a quicker time frame.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.